A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor α Agent

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504715-33-00

Acronym

CNTO1959PSA3005

Enrollment

229

Registered

2024-04-19

Start date

2021-09-27

Completion date

Unknown

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Brief summary

Proportion of participants who achieve an ACR 20 response at Week 24

Interventions

DRUGGuselkumab 1 mL PFS Placebo

DRUGGuselkumab - solution for injection in pre-filled syringe - 100 mg/mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of participants who achieve an ACR 20 response at Week 24	—

Countries

Bulgaria, Czechia, Hungary, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026